Literature DB >> 16288493

Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model.

Chara A Kyriakou1, Kwee L Yong, Reuben Benjamin, Arnold Pizzey, Ahmet Dogan, Nalini Singh, Andrew M Davidoff, Amit C Nathwani.   

Abstract

BACKGROUND: Efficient gene transfer to bone marrow derived mesenchymal stem cells (MSC) would provide an important opportunity to express potent anticancer agents in the tumour microenvironment because of their contribution to the tumour stroma.
METHODS: HIV-based lentiviral vectors were pseudotyped with four different envelope proteins; amphotropic murine leukaemia virus (ampho), murine leukaemia virus (10A1), feline endogenous virus (RD114), and the vesicular stomatitis virus glycoprotein (VSVG). These pseudotypes were examined for transduction efficiency in human bone marrow derived MSC. The effect of lentiviral expression of truncated soluble vascular endothelial growth factor decoy receptor (tsFlk-1) in MSC on growth of Raji cells was determined, both in vitro and in vivo.
RESULTS: All lentiviral vectors produced significant levels of transduction at an multiplicity of infection (MOI) of 1, those bearing the RD114 envelope glycoprotein consistently produced higher transduction levels (mean 70 +/- 6%) compared with the other pseudotyped lentiviral vectors, although there was significant inter-donor variation. Stable transgene expression was achieved after multiple rounds of transduction with VSVG-pseudotyped particles, without alteration in the differentiative capacity of transduced cells. Co-injection of MSC stably expressing tsFlk-1 with Raji Burkitt's lymphoma cells significantly impaired subcutaneous tumour growth in immunodeficient mice when compared to controls where either unmanipulated MSC or GFP-expressing MSC were used.
CONCLUSIONS: Human MSC are easily transduced by pseudotyped lentiviral particles but there is inter-donor variation in transduction efficiency. Gene-modified MSC expressing a gene of therapeutic potential can moderate growth of haematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16288493     DOI: 10.1002/jgm.840

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  18 in total

1.  The isolation and characterization of putative mesenchymal stem cells from the spiny mouse.

Authors:  Hayley Dickinson; Phillipa Milton; Graham Jenkin
Journal:  Cytotechnology       Date:  2012-02-26       Impact factor: 2.058

2.  A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions.

Authors:  Hui-Yuan Hou; Hong-Liang Liang; Yu-Sheng Wang; Zhao-Xia Zhang; Bai-Ren Wang; Yuan-Yuan Shi; Xiao Dong; Yan Cai
Journal:  Mol Ther       Date:  2010-07-20       Impact factor: 11.454

Review 3.  Gene therapy to create biological pacemakers.

Authors:  Gerard J J Boink; Jurgen Seppen; Jacques M T de Bakker; Hanno L Tan
Journal:  Med Biol Eng Comput       Date:  2006-10-18       Impact factor: 2.602

Review 4.  Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer.

Authors:  Qi Bao; Yue Zhao; Hanno Niess; Claudius Conrad; Bettina Schwarz; Karl-Walter Jauch; Ralf Huss; Peter J Nelson; Christiane J Bruns
Journal:  Stem Cells Dev       Date:  2012-06-26       Impact factor: 3.272

Review 5.  Mesenchymal stem cells as delivery vectors for anti-tumor therapy.

Authors:  Zhenzhen Li; Dongmei Fan; Dongsheng Xiong
Journal:  Stem Cell Investig       Date:  2015-03-26

Review 6.  Mesenchymal stem cells at the intersection of cell and gene therapy.

Authors:  Timothy J Myers; Froilan Granero-Molto; Lara Longobardi; Tieshi Li; Yun Yan; Anna Spagnoli
Journal:  Expert Opin Biol Ther       Date:  2010-12       Impact factor: 4.388

7.  Dual non-viral gene delivery from microparticles within 3D high-density stem cell constructs for enhanced bone tissue engineering.

Authors:  Alexandra McMillan; Minh Khanh Nguyen; Tomas Gonzalez-Fernandez; Peilin Ge; Xiaohua Yu; William L Murphy; Daniel J Kelly; Eben Alsberg
Journal:  Biomaterials       Date:  2018-01-03       Impact factor: 12.479

Review 8.  Practical Issues with the Use of Stem Cells for Cancer Gene Therapy.

Authors:  Faranak Salman Nouri; Debabrata Banerjee; Arash Hatefi
Journal:  Stem Cell Rev Rep       Date:  2015-10       Impact factor: 5.739

Review 9.  Stem cell paracrine actions and tissue regeneration.

Authors:  Priya R Baraniak; Todd C McDevitt
Journal:  Regen Med       Date:  2010-01       Impact factor: 3.806

Review 10.  Concise review: adult multipotent stromal cells and cancer: risk or benefit?

Authors:  Gwendal Lazennec; Christian Jorgensen
Journal:  Stem Cells       Date:  2008-04-03       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.